Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

NCT07077798 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

234

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Sintilimab
DRUG: Lenvatinib

Sponsor

Wan-Guang Zhang